Decoy Therapeutics Inc.
DCOY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.01 | 0.04 |
| FCF Yield | -254.33% | -75.30% | -73.07% | -49.71% |
| EV / EBITDA | 0.08 | -0.89 | -0.61 | 0.68 |
| Quality | ||||
| ROIC | -330.78% | -231.22% | -306.62% | -33.09% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 1.02 | 0.56 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 64.77% | 32.73% | -87.21% | 1.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.39 | 0.44 | 0.53 | 2.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |